Digital solidarity and adaptation: applications developed for refugees in host countries

Autor: Özlem Özdemir, Melih Görgün, Elif Başak Sarıoğlu

Publikováno v: Frontiers in Sociology, Vol 9 (2024)

The scale of international migration is growing day by day, and the issue of refugees constitutes a significant agenda item for all countries. In today's digital age, characterized by technological advancements, refugees are also benefiting from the

Externí odkaz: https://doaj.org/article/13e9faed6d134fdba1193ba046830417

Recovery from Respiratory Failure in Patients with Coronavirus Disease 2019

Autor: Serhat Erol, Aslıhan Gürün Kaya, Özlem Işık, Fatma Çiftçi, Güle Çınar, Çağlar Uzun, Alpay Azap, Aydın Çiledağ, Akın Kaya, Özlem Özdemir Kumbasar

Publikováno v: Thoracic Research and Practice, Vol 25, Iss 1, Pp 26-34 (2024)

OBJECTIVE: Coronavirus disease 2019 (COVID-19) can cause hypoxic respiratory failure; long-term oxygen therapy (LTOT) duration is unknown. MATERIAL AND METHODS: The aim was to investigate which patients would need LTOT after COVID-19 pneumonia. Th

Externí odkaz: https://doaj.org/article/27246cf3f8464c0f85158dcb0e5d99c0

Genç Tüketicilerde E-Ticaret Sitelerine Yönelik Marka Güveni ve Tüketici-Marka Özdeşleşmesinin Marka Evangelizmi Üzerine Etkisi

Autor: Sena Altın, Özlem Özdemir Süzer

Publikováno v: Cumhuriyet Üniversitesi İktisadi ve İdari Bilimler Dergisi, Vol 24, Iss 3, Pp 459-468 (2023)

Marka güveni ve tüketici-marka özdeşleşmesi, marka evangelizmi üzerinde önemli bir etkiye sahiptir. Marka güveni, bir tüketicinin bir markaya duyduğu güven duygusudur. Markanın mal ve hizmetlerinin kalitesi, güvenilirliği ve sadakati il

Externí odkaz: https://doaj.org/article/1de3d83512b24a5d8419074bd896ea6d

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Autor: Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, Merve Keskinkılıç, Naziyet Köse Baytemür, Funda Yılmaz, Oğuzhan Selvi, Dilek Erdem, Esin Avşar, Nail Paksoy, Necla Demir, Sema Sezgin Göksu, Sema Türker, Ertuğrul Bayram, Abdüssamet Çelebi, Hatice Yılmaz, Ömer Faruk Kuzu, Seda Kahraman, İvo Gökmen, Abdullah Sakin, Ali Alkan, Erdinç Nayır, Muzaffer Uğraklı, Ömer Acar, İsmail Ertürk, Hacer Demir, Ferit Aslan, Özlem Sönmez, Taner Korkmaz, Özde Melisa Celayir, İbrahim Karadağ, Erkan Kayıkçıoğlu, Teoman Şakalar, İlker Nihat Öktem, Tülay Eren, Enes Erul, Eda Eylemer Mocan, Ziya Kalkan, Nilgün Yıldırım, Yakup Ergün, Baran Akagündüz, Serdar Karakaya, Engin Kut, Fatih Teker, Burçin Çakan Demirel, Kubilay Karaboyun, Elvina Almuradova, Olçun Ümit Ünal, Abdilkerim Oyman, Deniz Işık, Kerem Okutur, Buğra Öztosun, Burcu Belen Gülbağcı, Mehmet Emin Kalender, Elif Şahin, Mustafa Seyyar, Özlem Özdemir, Fatih Selçukbiricik, Metin Kanıtez, İsa Dede, Mahmut Gümüş, Erhan Gökmen, Arzu Yaren, Serkan Menekşe, Senar Ebinç, Sercan Aksoy, Gökşen İnanç İmamoğlu, Mustafa Altınbaş, Bülent Çetin, Başak Oyan Uluç, Özlem Er, Nuri Karadurmuş, Atike Pınar Erdoğan, Mehmet Artaç, Özgür Tanrıverdi, İrfan Çiçin, Mehmet Ali Nahit Şendur, Esin Oktay, İbrahim Vedat Bayoğlu, Semra Paydaş, Adnan Aydıner, Derya Kıvrak Salim, Çağlayan Geredeli, Tuğba Yavuzşen, Mutlu Doğan, İlhan Hacıbekiroğlu

Publikováno v: BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)

Abstract Background There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment

Externí odkaz: https://doaj.org/article/042edc2981bf4d52a01526b7a7c03f4f

A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry

Autor: Ayten Yazici, Özlem Özdemir Işık, Ediz Dalkılıç, Süleyman Serdar Koca, Yavuz Pehlivan, Soner Şenel, Nevsun Inanc, Servet Akar, Sema Yılmaz, Özgül Soysal Gündüz, Ayse Cefle, Ömer Fatih Karakaş, Fatos Onen

Publikováno v: Scientific Reports, Vol 12, Iss 1, Pp 1-7 (2022)

Abstract Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody that targets the IL-6 receptor. TCZ found to be efficacious and has a good tolerated safety profile in rheumatoid arthritis (RA) patients. The aim of this study was to describe

Externí odkaz: https://doaj.org/article/19120a1a963b4c70ac0f49b9a53e4fb6